http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2005060951-A3

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cfae6e97c048865df239daf4acf049a9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4bf6b40220880e3b46fc3b230e03f7d1
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-10
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-155
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-167
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4709
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-216
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-498
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5011
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-704
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-122
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4709
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-122
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-498
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-167
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-155
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-216
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-704
filingDate 2004-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f2755bf36096ae565daccf27e76464fd
publicationDate 2005-11-24-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2005060951-A3
titleOfInvention Anti-neoplastic agents, combination therapies and related methods
abstract In certain aspects, the invention relates to the discovery of novel compositions for use in the treatment of a neoplastic disorder. Active agents are e.g. ouabain, niclosamide, casodex. Further aspects of the invention relate to the discovery that cell signaling may be exploited to identify significant genes in cancer cell lines and to generate reporter gene systems that may be used, for example, to identify anti-neoplastic agents and effective combinations thereof.
priorityDate 2003-12-19-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2004047842-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2004006906-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9925344-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9728808-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0191740-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9856390-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0006143-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2375
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419505939
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419486648
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID439501
http://rdf.ncbi.nlm.nih.gov/pubchem/taxonomy/TAXID141614
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419479559
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395752
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395753
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID56069
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226448111
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID433323045
http://rdf.ncbi.nlm.nih.gov/pubchem/anatomy/ANATOMYID141614
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226405821
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4477
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID154497143

Total number of triples: 53.